Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication

Journal of Cellular Biochemistry

Volumn 114, Issue 9, 2013, Pages 1987-1996

  Sato, Ayami ^a   Saito, Yoshimasa ^a,b   Sugiyama, Kazuo ^b   Sakasegawa, Noriko ^a   Muramatsu, Toshihide ^a   Fukuda, Shinya ^a   Yoneya, Mikiko ^a   Kimura, Masaki ^a   Ebinuma, Hirotoshi ^b   Hibi, Toshifumi ^b   Ikeda, Masanori ^c   Kato, Nobuyuki ^c   Saito, Hidetsugu ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

APOLIPOPROTEIN A1; HEPATITIS C VIRUS; MIR 122; OR6; OSTEOPONTIN; SUBEROYLANILIDE HYDROXAMIC ACID

Indexed keywords

APOLIPOPROTEIN A1; MICRORNA; MICRORNA 122; OSTEOPONTIN; VIRUS RNA; VORINOSTAT;

ANTIVIRAL ACTIVITY; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE INDUCTION; GENE SILENCING; HEPATITIS C VIRUS; HISTONE ACETYLATION; HOST CELL; HOST RESISTANCE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 84881390839     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24541     Document Type: Article

References (48)

1. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT, Glimcher MJ, Cantor H,. 2000. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
2. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM,. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99: 11700-11705.
3. Chen YC, Su WC, Huang JY, Chao TC, Jeng KS, Machida K, Lai MM,. 2010. Polo-like kinase 1 is involved in hepatitis C virus replication by hyperphosphorylating NS5A. J Virol 84: 7983-7993.
4. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS,. 2009. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536.
5. Duan H, Heckman CA, Boxer LM,. 2005. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619.
6. Ebinuma H, Saito H, Tada S, Nakamoto N, Ohishi T, Tsunematsu S, Kumagai N, Tsuchimoto K, Tsukada N, Inagaki Y, Horie Y, Takahashi M, Atsukawa K, Okamura Y, Kanai T, Hibi T,. 2012. Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: An analysis using the propensity score. Hepatol Int 6: 744-752.
7. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP,. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
8. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L,. 2009. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69: 5761-5767.
9. Gal-Yam EN, Saito Y, Egger G, Jones PA,. 2008. Cancer epigenetics: Modifications, screening, and therapy. Annu Rev Med 59: 267-280.
10. Gao L, Aizaki H, He JW, Lai MM,. 2004. Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft. J Virol 78: 3480-3488.
11. Haas MJ, Alamir AR, Sultan S, Chehade JM, Wong NC, Mooradian AD,. 2011. Nicotinic acid induces apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 60: 1790-1796.
12. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M,. 2010. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 5: 82.
13. Hamamoto I, Nishimura Y, Okamoto T, Aizaki H, Liu M, Mori Y, Abe T, Suzuki T, Lai MM, Miyamura T, Moriishi K, Matsuura Y,. 2005. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol 79: 13473-13482.
14. Horscroft N, Lai VC, Cheney W, Yao N, Wu JZ, Hong Z, Zhong W,. 2005. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir Chem Chemother 16: 1-12.
15. Ikeda M, Abe K, Dansako H, Nakamura T, Naka K, Kato N,. 2005. Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. Biochem Biophys Res Commun 329: 1350-1359.
16. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N,. 2006. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44: 117-125.
17. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P,. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
18. Kanamori H, Kawakami T, Effendi K, Yamazaki K, Mori T, Ebinuma H, Masugi Y, Du W, Nagasaka K, Ogiwara A, Kyono Y, Tanabe M, Saito H, Hibi T, Sakamoto M,. 2011. Identification by differential tissue proteome analysis of talin-1 as a novel molecular marker of progression of hepatocellular carcinoma. Oncology 80: 406-415.
19. Kaneko F, Saito H, Saito Y, Wakabayashi K, Nakamoto N, Tada S, Suzuki H, Tsunematsu S, Kumagai N, Ishii H,. 2004. Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol 24: 837-845.
20. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R,. 2009. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 5: e1000546.
21. Kurita S, Higuchi H, Saito Y, Nakamoto N, Takaishi H, Tada S, Saito H, Gores GJ, Hibi T,. 2010. DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8. Cancer Sci 101: 1431-1439.
22. Lauer GM, Walker BD,. 2001. Hepatitis C virus infection. N Engl J Med 345: 41-52.
23. Liang G, Lin JC, Wei V, Yoo C, Cheng JC, Nguyen CT, Weisenberger DJ, Egger G, Takai D, Gonzales FA, Jones PA,. 2004. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci USA 101: 7357-7362.
24. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R,. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
25. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, Chen CS,. 2007. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 46: 1119-1130.
26. Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, Longo MA, D'Offizi G, Di Giacomo C, Pucillo LP, Amicone L, Tripodi M, Alonzi T,. 2011. Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut 60: 378-386.
27. Masuda T, Saito H, Kaneko F, Atsukawa K, Morita M, Inagaki H, Kumagai N, Tsuchimoto K, Ishii AH,. 2000. Up-regulation of E-cadherin and I-catenin in human hepatocellular carcinoma cell lines by sodium butyrate and interferon-alpha. In Vitro Cell Dev Biol Anim 36: 387-394.
28. Mishiro T, Ishihara K, Hino S, Tsutsumi S, Aburatani H, Shirahige K, Kinoshita Y, Nakao M,. 2009. Architectural roles of multiple chromatin insulators at the human apolipoprotein gene cluster. EMBO J 28: 1234-1245.
29. Mochida S, Hashimoto M, Matsui A, Naito M, Inao M, Nagoshi S, Nagano M, Egashira T, Mishiro S, Fujiwara K,. 2004. Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 313: 1079-1085.
30. Naito M, Matsui A, Inao M, Nagoshi S, Nagano M, Ito N, Egashira T, Hashimoto M, Mishiro S, Mochida S, Fujiwara K,. 2005. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 40: 381-388.
31. Nakamura M, Saito H, Ebinuma H, Wakabayashi K, Saito Y, Takagi T, Nakamoto N, Ishii H,. 2001. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. J Cell Physiol 187: 392-401.
32. Nakamura M, Saito H, Ikeda M, Tada S, Kumagai N, Kato N, Shimotohno K, Hibi T,. 2008. Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. J Med Virol 80: 632-639.
33. Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, Moriishi K, Matsuura Y,. 2006. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 25: 5015-5025.
34. Patarca R, Saavedra RA, Cantor H,. 1993. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 13: 225-246.
35. Qiao L, Schaack J, Shao J,. 2006. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 147: 865-874.
36. Saito H, Ebinuma H, Takahashi M, Kaneko F, Wakabayashi K, Nakamura M, Ishii H,. 1998. Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Hepatology 27: 1233-1240.
37. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA,. 2006. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443.
38. Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K, Saito H, Hibi T,. 2011. MicroRNAs in hepatobiliary and pancreatic cancers. Front Genet 2: 66.
39. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W,. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15: 31-33.
40. Schickel R, Boyerinas B, Park SM, Peter ME,. 2008. MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27: 5959-5974.
41. Takayama T, Ebinuma H, Tada S, Yamagishi Y, Wakabayashi K, Ojiro K, Kanai T, Saito H, Hibi T,. 2011. Prediction of effect of pegylated interferon alpha-2b plus ribavirin combination therapy in patients with chronic hepatitis C infection. PLoS ONE 6: e27223.
42. Tu H, Gao L, Shi ST, Taylor DR, Yang T, Mircheff AK, Wen Y, Gorbalenya AE, Hwang SB, Lai MM,. 1999. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. Virology 263: 30-41.
43. Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G,. 2012. Evaluation of phosphatidylinositol-4-kinase IIIalpha as a hepatitis C virus drug target. J Virol 86: 11595-11607.
44. Wakabayashi K, Saito H, Ebinuma H, Saito Y, Takagi T, Nakamura M, Umezawa A, Hata J, Ishii H,. 2000. Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period. Oncol Rep 7: 285-288.
45. Wakabayashi K, Saito H, Kaneko F, Nakamoto N, Tada S, Hibi T,. 2005. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int J Oncol 26: 233-239.
46. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ,. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
47. Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Miyagi-Maesima A, Matsuno Y, Tobinai K,. 2010. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101: 196-200.
48. Yoo CB, Jones PA,. 2006. Epigenetic therapy of cancer: Past, present and future. Nat Rev Drug Discov 5: 37-50.